Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity

Summary

The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and quality of life assessment in participants with neurogenic detrusor overactivity (NDO - the nerves mediating the detrusor muscle do not work properly leading to frequent feeling of need to urinate during the day, night, or both).

Timeline

Start

2008-12

Primary completion

2010-12

Completion

2010-12

Drugs

Indications